Please assess the completion status of the following clinical trial:

Trial Title: Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female participants of childbearing potential must have negative pregnancy test and use appropriate contraceptive methods~* Documented GHD during adulthood~* Participants naive to somavaratan must have an IGF-1 SDS value ≤ 0 at Screening~* Participants taking other hormone replacement therapy must have been on a stable course of treatment for at least 3 months~* Underlying disorders responsible for the participant's GHD must have been clinically stable for at least 6 months~* Participants receiving daily rhGH injections must washout for ≥ 14 days~* Body mass index (BMI) (kilograms \[kg\]/meter square \[m\^2\]) between 18.0 and 40.0~Exclusion Criteria:~* Untreated adrenal insufficiency~* Recently diagnosed thyroid dysfunction which is not being treated or has not been stable on therapy for at least 3 months~* Currently taking anti-inflammatory dose of glucocorticoids that could potentially compromise safety or efficacy assessments~* Currently taking a GHRH or IGF-I product~* Current significant cardiovascular disease, heart insufficiency of New York Heart Association (NYHA) class \> 2~* Current significant disease thought to increase risk of receiving growth hormone or confound assessment of study outcomes~* History of diabetes mellitus or inadequate glucose control~* Current drug or alcohol abuse~* Current human immunodeficiency virus (HIV) wasting syndrome (HIV testing not required)~* History of malignancy in adulthood (participants with a history of childhood malignancy that were subsequently treated with rhGH in childhood and remain GHD in adulthood may be enrolled)~* Women who are pregnant or breastfeeding~* Treatment with an investigational drug other than somavaratan within 30 days prior to Screening~* A significant abnormality in Screening laboratory results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Somavaratan (Type: EXPERIMENTAL): Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly in adult participants with GHD

Based on this trial design, predict the completion outcome and termination type (if applicable).